Related Experiment Video

Updated: May 17, 2025

Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis
10:04

Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis

Published on: May 1, 2015

13.0K

T-Cell Engagers In Multiple Myeloma: A Clinical Review

Ahmad Al-Jarrad1, Samhar Samer Alouch1, Yogesh Chawla1

  • 1Division of Hematology, Mayo Clinic, Rochester, MN, USA.

Blood and Lymphatic Cancer : Targets and Therapy
|March 31, 2025
PubMed

Insights

T-cell engagers targeting BCMA and GPRC5D show high response rates in relapsed/refractory multiple myeloma. Further research aims to improve efficacy and reduce side effects for next-generation therapies.

Area of Science:

  • Oncology
  • Immunology
  • Biotechnology

Background:

  • T-cell engagers (TCEs) leverage T-cell activity against cancer.
  • BCMA- and GPRC5D-targeted TCEs show promise in multiple myeloma.

Purpose of the Study:

  • To review the clinical activity and toxicities of BCMA- and GPRC5D-targeted TCEs.
  • To discuss the future directions for TCE development in multiple myeloma.

Main Methods:

  • Review of clinical trial data for TCEs targeting BCMA and GPRC5D.
  • Analysis of response rates, durability, and safety profiles.

Main Results:

  • TCE monotherapy achieved over 60% overall response rates in relapsed/refractory multiple myeloma.
  • Deep and durable hematological responses were observed.
  • Common toxicities included cytokine release syndrome and infections.

Conclusions:

  • BCMA- and GPRC5D-targeted TCEs are effective in heavily pretreated multiple myeloma patients.
  • Ongoing research focuses on enhancing efficacy and tolerability for future TCE generations.
Keywords:
BCMAGPRC5DT-cell engagersmultiple myeloma

More Related Videos

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells09:41

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells

Published on: July 15, 2015

8.6K
Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice05:32

Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice

Published on: January 7, 2019

6.7K

Related Concept Videos

T Cell Activation and Clonal Selection01:22

T Cell Activation and Clonal Selection

T cells are integral to our adaptive immune system, recognizing and effectively responding to foreign antigens. T cell activation and clonal selection are pivotal in orchestrating this immune response. This article elucidates these mechanisms, detailing the roles of cluster of differentiation (CD) markers, major histocompatibility complex (MHC) molecules, costimulatory signals, and the process of clonal selection.
Naive T cells that have not yet encountered an antigen express two primary CD...
596
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
432
The Tumor Microenvironment02:17

The Tumor Microenvironment

Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
6.5K